News Zai Lab Limited Hong Kong S.E.

Equities

9688

KYG9887T1168

Delayed Hong Kong S.E. Other stock markets 23:59:50 2024-05-23 EDT			5-day change	1st Jan Change
14.34 ^HKD	-5.66%		-7.48%	-33.30%

05-22	Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise	MT
05-20	Chinese Regulator Approves Zai Lab’s New Drug Application for Bacterial Pneumonia Drug	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise	05-22	MT
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis	05-22	BU
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	05-21	AQ
Chinese Regulator Approves Zai Lab’s New Drug Application for Bacterial Pneumonia Drug	05-20	MT
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment	05-20	MT
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	05-20	BU
Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading	05-16	MT
Zai Lab Announces Participation in May and June Investor Conferences	05-16	BU
Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator	05-14	MT
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China	05-14	BU
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy in China	05-14	CI
Zai Lab Announces Approval of AUGTYRO for Patients with ROS1-positive NSCLC by China's NMPA	05-13	AQ
Asian Equities Traded in the US as American Depositary Receipts Begin Week Higher	05-13	MT
Zai Lab Says China Approves New Drug Application for Lung Cancer Treatment Augtyro	05-13	MT
Zai Lab's Cancer Drug Gets NDA Approval in China	05-12	MT
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA	05-12	BU
Zai Lab's Shares Rise After Q1 Beat	05-09	MT
Asian Equities Traded in the US as American Depositary Receipts Trend Lower Thursday	05-09	MT
Top Premarket Gainers	05-09	MT
Transcript : Zai Lab Limited, Q1 2024 Earnings Call, May 09, 2024	05-09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Zai Lab Limited Hong Kong S.E.

Equities

9688

KYG9887T1168

Summary

Filters